Abstract
Imidazole derivatives have known to possess a diverse range of pharmacological activity. In particular, one of ruthenium-based derivatives, imidazolium [trans-RuCl4(1H-imidazole)(DMSOS)] (NAMI-A) which is now in clinical trials, opens a new avenue for developing promising ruthenium-based anticancer drugs alternative to Cisplatin. This mini-review overviews some representative examples of imidazole-containing ruthenium complexes (ICRCs) with in vitro anticancer activities. Special attention is paid on ICRCs with the activities more potent than Cisplatin, and their correlation with their DNA binding properties in the context of possible cancer chemotherapeutic applications. The ICRCs are divided into two main categories according to their dark and light activated cytotoxicity; the former case is further clarified into mononuclear complexes including tris(bidentate polypyridyl) ruthenium complexes and those containing monodentatively coordinative imidazole ligands as well as polynuclear complexes. The perspective, challenges and future efforts for investigations into ICRCs are pointed out or suggested.
Keywords: Anticancer agent, Cytotoxity, DNA, Imidazole, Photocytotoxity, Ruthenium.
Mini-Reviews in Medicinal Chemistry
Title:Recent Advances on Dark and Light-Activated Cytotoxity of Imidazole- Containing Ruthenium Complexes
Volume: 16 Issue: 4
Author(s): Ping Liu, Jia Jia, Yue Zhao and Ke-Zhi Wang
Affiliation:
Keywords: Anticancer agent, Cytotoxity, DNA, Imidazole, Photocytotoxity, Ruthenium.
Abstract: Imidazole derivatives have known to possess a diverse range of pharmacological activity. In particular, one of ruthenium-based derivatives, imidazolium [trans-RuCl4(1H-imidazole)(DMSOS)] (NAMI-A) which is now in clinical trials, opens a new avenue for developing promising ruthenium-based anticancer drugs alternative to Cisplatin. This mini-review overviews some representative examples of imidazole-containing ruthenium complexes (ICRCs) with in vitro anticancer activities. Special attention is paid on ICRCs with the activities more potent than Cisplatin, and their correlation with their DNA binding properties in the context of possible cancer chemotherapeutic applications. The ICRCs are divided into two main categories according to their dark and light activated cytotoxicity; the former case is further clarified into mononuclear complexes including tris(bidentate polypyridyl) ruthenium complexes and those containing monodentatively coordinative imidazole ligands as well as polynuclear complexes. The perspective, challenges and future efforts for investigations into ICRCs are pointed out or suggested.
Export Options
About this article
Cite this article as:
Liu Ping, Jia Jia, Zhao Yue and Wang Ke-Zhi, Recent Advances on Dark and Light-Activated Cytotoxity of Imidazole- Containing Ruthenium Complexes, Mini-Reviews in Medicinal Chemistry 2016; 16(4) . https://dx.doi.org/10.2174/1389557516666151120120524
DOI https://dx.doi.org/10.2174/1389557516666151120120524 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Polymorphisms in Methotrexate Pathways: What Is Clinically Relevant, What Is Not, and What Is Promising
Current Drug Metabolism Impact of microRNAs in Resistance to Chemotherapy and Novel Targeted Agents in Non-Small Cell Lung Cancer
Current Pharmaceutical Biotechnology Nutrition Support of Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
Current Nutrition & Food Science Apoptosis Suppression by Candidate Oncogene PLAC8 is Reversed in Other Cell Types
Current Cancer Drug Targets Alteration of Ceramide 1-O-Functionalization as a Promising Approach for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Multi-Targeted Agents in Cancer Cell Chemosensitization: What We Learnt from Curcumin Thus Far
Recent Patents on Anti-Cancer Drug Discovery Chlorophylls and their Derivatives Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry Towards Cure of CML: Why We Need to Know More About CML Stem Cells?
Current Stem Cell Research & Therapy FLT3 Inhibition in Acute Myeloid Leukaemia – Current Knowledge and Future Prospects
Current Cancer Drug Targets Current Strategies to Target the Anti-Apoptotic Bcl-2 Protein in Cancer Cells
Current Medicinal Chemistry Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics
Current Medicinal Chemistry Glycogen Synthase Kinase 3 as an Anticancer Drug Target: Novel Experimental Findings and Trends in the Design of Inhibitors
Current Pharmaceutical Design A Review on Antiproliferative and Apoptotic Activities of Natural Honey
Anti-Cancer Agents in Medicinal Chemistry Regulation and Function of DNA and Histone Methylations
Current Pharmaceutical Design RNA Interference: A New Targeted Tumour Therapy?
Current Cancer Therapy Reviews Chemistry of Tumour Targeted T1 Based MRI Contrast Agents
Current Topics in Medicinal Chemistry Ribonucleases, Nucleases and Antiangiogenins in Antiproliferative Activities
Current Signal Transduction Therapy Histone Deacetylase Inhibitors: New Promise in the Treatment of Immune and Inflammatory Diseases
Current Drug Targets Therapeutic Proteins in Tumors and Targeted Therapeutic Agents for Cancer Patients
Protein & Peptide Letters Specific Targeting of HER2-Positive Head and Neck Squamous Cell Carcinoma Line HN5 by Idarubicin-ZHER2 Affibody Conjugate
Current Cancer Drug Targets